The TNF-α antagonist, infliximab, reduces plasma leptin levels in BD patients by modulating soluble tumor necrosis factor receptor 2, contributing to better performance on non-literal memory tasks and increased overall cortical volume, both of which are negatively correlated with the leptin level (Mansur et al., 2020). This evidence concerns the gene LEP and Behcet disease.